



Remarks

The application was objected to. A copy of the printed patent is provided herewith in double column form as required under 37 C.F.R. §1.173(a)(1). The objection is thus obviated.

Claim 1 was rejected under 35 U.S.C. §251 as being broadened in a reissue application beyond the two year statutory period because it was maintained that by Claim 1, Applicants claim all trans-retinoid acids and thus encompass every one of the trans retinoic acids in a pharmacologic effective amount to increase plasma HDL levels. Applicants have amended Claim 1 to clearly delineate that they intend to claim all trans retinoic acid, (i.e. tretinoin) by removal of a hyphen between the words all and trans. Support for this amendment can be found at, for example, Column 2, lines 48-49. The amendment is meant to correct any possible confusion, and is not meant to change the intended scope of the claim. This rejection has been overcome.

Claim 1 was rejected under 35 U.S.C. §112, second paragraph as being unclear what is meant by "all-trans-retinoic acid". As discussed above, Applicants have amended Claim 1. This rejection is moot.

In view of the foregoing, Applicants maintain that Claim 1 is in condition ready for allowance. Reissue of U.S. Patent No. 5,219,888 is respectfully requested.

Rebecca R. Barrett
June 3, 2005
Attorney for Applicants
Reg. No. 35,152

Wyeth
Patent Law Department
Five Giralda Farms
Madison, NJ 07940
Tel. No. (484) 865-8607